The chief business officer of US pharmaceutical company Pfizer Inc, John Young, has said that the company expects to deliver over 13 million doses of its COVID-19 vaccine per week to the US by the middle of March 2021, more than doubling its shipments from early February 2021, Reuters news agency reported on Tuesday.

According to Young, Pfizer is on track to deliver 120 million doses of its two-dose regimen by the end of March 2021.

Pfizer is also prepared to provide a total of 300 million vaccine doses to the US by the end of July 2021 and has raised global production expectations for 2021 to at least two billion doses, Young said.

The president of US pharmaceutical company Moderna Inc has said that the company plans to deliver 100 million doses of its two-dose shot by the end of March and 300 million by the end of July 2021.

According to the vice president of Medical Affairs of Johnson & Johnson (J&J), Richard Nettles, J&J believes it will be able to ship at least 20 million doses of its single-dose shot to the US by the end of March after receiving US regulatory authorization and 100 million doses by mid-year 2021.

These comments were prepared ahead of a US congressional hearing on vaccine availability to be held by the House Committee on Energy and Commerce on 23 February 2021. This put the US on track to receive 240 million COVID-19 vaccine doses by the end of March 2021, enough to inoculate 130 million Americans,

In addition, the company president, North America of British pharmaceutical company AstraZeneca Plc, Ruud Dobber, said that the company can quickly adapt its shot to new COVID-19 virus variants in its laboratory.

Currently, AstraZeneca is running a US trial for its COVID-19 vaccine.